GLP-1 drugs are a class of medications that mimic the gut hormone glucagon-like peptide-1 to lower blood sugar, slow gastric emptying, and reduce appetite. FDA-approved GLP-1 drugs include Ozempic, Wegovy, Trulicity, Victoza, and Saxenda, along with the oral tablet Rybelsus. Mounjaro and Zepbound (tirzepatide) are dual GIP/GLP-1 agonists and are usually grouped with this class. Side effects are predominantly gastrointestinal, and serious risks are rare but important. Here is how they work, what the benefits look like, and what the FDA label warns about.
How GLP-1 Drugs Work
GLP-1 is a natural hormone released by intestinal cells after you eat. It tells the pancreas to release insulin in response to food, suppresses the glucose-raising hormone glucagon, slows how quickly food leaves the stomach, and signals satiety to the brain. Natural GLP-1 is broken down within minutes — too quickly to be a useful medication on its own.
GLP-1 receptor agonists are engineered to resist breakdown, so they stay in the bloodstream for hours or days. That lets them do the same job as natural GLP-1 for longer. Most are injected once weekly (Ozempic, Trulicity, Wegovy, Bydureon) or once daily (Victoza, Saxenda), with Rybelsus the only oral semaglutide tablet.
FDA-Approved GLP-1 Drugs at a Glance
| Brand Name | Generic | Frequency | Primary Indication |
|---|---|---|---|
| Ozempic | Semaglutide | Weekly injection | Type 2 diabetes (and CV risk) |
| Wegovy | Semaglutide 2.4 mg | Weekly injection | Weight management (and CV risk) |
| Rybelsus | Semaglutide | Daily oral tablet | Type 2 diabetes |
| Trulicity | Dulaglutide | Weekly injection | Type 2 diabetes |
| Victoza | Liraglutide | Daily injection | Type 2 diabetes |
| Saxenda | Liraglutide 3 mg | Daily injection | Weight management |
| Byetta / Bydureon | Exenatide | Twice daily / weekly | Type 2 diabetes |
| Mounjaro | Tirzepatide (GIP/GLP-1) | Weekly injection | Type 2 diabetes |
| Zepbound | Tirzepatide (GIP/GLP-1) | Weekly injection | Weight management |
Benefits Shown in Clinical Trials
- Glucose control: A1C reductions of roughly 1-2% across the class when used for type 2 diabetes.
- Weight loss: 5-8% with older GLP-1s like liraglutide and dulaglutide; 10-15% with semaglutide; 15-20% with tirzepatide at higher doses.
- Cardiovascular risk reduction: The ADA Standards of Care recommend a GLP-1 with proven CV benefit in people with type 2 diabetes and established atherosclerotic cardiovascular disease or high risk. The SELECT trial extended semaglutide’s CV benefit to adults with obesity even without diabetes.
- Kidney outcomes: Recent trials such as FLOW (semaglutide) showed reduced progression of kidney disease in people with type 2 diabetes and chronic kidney disease.
Common Side Effects
Side effects are overwhelmingly gastrointestinal and concentrated during dose titration:
- Nausea (the most common, reported by 20-44% depending on drug and dose)
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain, dyspepsia, and bloating
- Headache and fatigue during early weeks
- Injection-site reactions (mild redness or itching)
Most reactions are mild to moderate and improve with continued treatment and slower dose escalation.
Serious but Rare Risks
- Boxed warning — thyroid C-cell tumors: Based on rodent studies; contraindicated with personal or family history of MTC or MEN 2
- Acute pancreatitis: Stop and seek care for severe, persistent abdominal pain
- Gallbladder disease: Rapid weight loss increases stone risk
- Acute kidney injury: Typically from dehydration with vomiting or diarrhea
- Hypoglycemia: Uncommon alone but common with insulin or sulfonylureas
- Diabetic retinopathy progression: Can briefly worsen with rapid glucose improvement
- Serious allergic reactions and injection-site reactions
Where GLP-1 Drugs Fit in Clinical Practice
For type 2 diabetes, GLP-1 drugs are often recommended as second-line after metformin, especially when weight loss or cardiovascular protection is a priority. For obesity, semaglutide 2.4 mg and tirzepatide 15 mg have the strongest evidence and largest average weight loss. For prediabetes, lifestyle change remains first-line — prediabetes is often reversible with diet, activity, and modest weight loss without medication. GLP-1 drugs are sometimes considered when lifestyle alone hasn’t worked and weight management is a treatment priority.
Practical Considerations Before Starting
- Review your full medical history with a clinician, especially thyroid cancer history, pancreatitis, gallbladder disease, or severe GI conditions
- Expect dose titration over 4 to 20 weeks depending on the specific drug
- Plan for ongoing follow-up; most benefits require continued use
- Discuss cost and insurance coverage — not all GLP-1 drugs are on every formulary
- Build in adequate protein and physical activity to protect muscle during weight loss
- Monitor A1C, kidney function, and lipids periodically as your clinician recommends
The Bottom Line
GLP-1 drugs have become a major tool for type 2 diabetes and chronic weight management, with meaningful benefits for blood sugar, weight, cardiovascular risk, and kidney outcomes. Their side-effect profile is well-characterized — mostly gastrointestinal and improvable with slow titration — and their serious risks are rare but well-known. Always work with a qualified clinician to weigh benefits, risks, and alternatives in your specific situation.
This article is educational and does not replace personalized medical advice.
